Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
China Car Sales Drop Again as EV Export Growth Surges in April 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
